Previous 10 | Next 10 |
Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...
Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The complement system is a part of the body's immune system. According to the company ARO...
- Achieved Mean Reductions of 88% in C3 and 91% in AH50 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed...
Summary Arrowhead Pharmaceuticals, Inc. is a company with strong potential. However, it has yet to conclusively prove the worth of any part of its vast pipeline. I will stick to the sideline on Arrowhead Pharmaceuticals, Inc. until that happens. In my previous coverage ...
Johnson & Johnson's ( NYSE: JNJ ) Janssen unit has relinquished rights to a RNAi candidate for non-alcoholic steatohepatitis ( NASH ), returning rights to Arrowhead Pharmaceuticals ( NASDAQ: ARWR ). The candidate, ARO-PNPLA3 (formerly JNJ-75220795), is an RNAi therapeu...
- Achieved Up to 40% Mean Reduction in Liver Fat in PNPLA3 I148M Homozygotes After Single-Dose Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option ag...
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2023 Earnings Conference Call February 6, 2023 16:30 ET Company Participants Vincent Anzalone - Vice President, Investor Relations Christopher Anzalone - President and Chief Executive Officer Javier San Martin - Chief Medical O...
Arrowhead Pharmaceuticals' ( NASDAQ: ARWR ) 128% year-over-year increase in revenue in fiscal 2023 Q1 is due in part to milestone payments from Amgen ( AMGN ) and Horizon Therapeutics ( HZNP ). The company recorded ~$62.6M in revenue in the quarter. In October 2022, ...
Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): Q1 EPS of -$0.39 may not be comparable to consensus of $0.13. Revenue of $62.55M (+128.3% Y/Y). For further details see: Arrowhead PharmaceuticalsEPS of -$0.39, revenue of $62.55M
- Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022. The company is hosting a conference call today, February 6, 2023, at 4:30 p.m. ET to...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...